Cargando…
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
PURPOSE: To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). METHODS: The IMRT dose distribution, location of the center of mass, sphericity, and solidity of t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622513/ https://www.ncbi.nlm.nih.gov/pubmed/36053452 http://dx.doi.org/10.1007/s11060-022-04123-3 |
_version_ | 1784821786846691328 |
---|---|
author | Shidoh, Satoka Savjani, Ricky R. Cho, Nicholas S. Ullman, Henrik E. Hagiwara, Akifumi Raymond, Catalina Lai, Albert Nghiemphu, Phionah L. Liau, Linda M. Pope, Whitney B. Cloughesy, Timothy F. Kaprealian, Tania B. Salamon, Noriko Ellingson, Benjamin M. |
author_facet | Shidoh, Satoka Savjani, Ricky R. Cho, Nicholas S. Ullman, Henrik E. Hagiwara, Akifumi Raymond, Catalina Lai, Albert Nghiemphu, Phionah L. Liau, Linda M. Pope, Whitney B. Cloughesy, Timothy F. Kaprealian, Tania B. Salamon, Noriko Ellingson, Benjamin M. |
author_sort | Shidoh, Satoka |
collection | PubMed |
description | PURPOSE: To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). METHODS: The IMRT dose distribution, location of the center of mass, sphericity, and solidity of the contrast enhancing tumor at baseline and the time of tumor recurrence was quantified in 48 IDH wild-type GBM who underwent postoperative IMRT (2 Gy daily for total of 60 Gy) with concomitant and adjuvant temozolomide. RESULTS: Average radiation dose within enhancing tumor at baseline and recurrence was ≥ 60 Gy. Centroid location of the enhancing tumor shifted an average of 11.3 mm at the time of recurrence with respect to pre-IMRT location. A positive correlation was observed between change in centroid location and PFS in MGMT methylated patients (P = 0.0007) and Cox multivariate regression confirmed centroid distance from baseline was associated with PFS when accounting for clinical factors (P = 0.0189). Lesion solidity was higher at recurrence compared to baseline (P = 0.0118). Tumors that progressed > 12 weeks after IMRT were significantly more spherical (P = 0.0094). CONCLUSION: Most GBMs recur local within therapeutic IMRT doses; however, tumors with longer PFS occurred further from the original tumor location and were more solid and/or nodular. |
format | Online Article Text |
id | pubmed-9622513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-96225132022-11-02 Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation Shidoh, Satoka Savjani, Ricky R. Cho, Nicholas S. Ullman, Henrik E. Hagiwara, Akifumi Raymond, Catalina Lai, Albert Nghiemphu, Phionah L. Liau, Linda M. Pope, Whitney B. Cloughesy, Timothy F. Kaprealian, Tania B. Salamon, Noriko Ellingson, Benjamin M. J Neurooncol Research PURPOSE: To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). METHODS: The IMRT dose distribution, location of the center of mass, sphericity, and solidity of the contrast enhancing tumor at baseline and the time of tumor recurrence was quantified in 48 IDH wild-type GBM who underwent postoperative IMRT (2 Gy daily for total of 60 Gy) with concomitant and adjuvant temozolomide. RESULTS: Average radiation dose within enhancing tumor at baseline and recurrence was ≥ 60 Gy. Centroid location of the enhancing tumor shifted an average of 11.3 mm at the time of recurrence with respect to pre-IMRT location. A positive correlation was observed between change in centroid location and PFS in MGMT methylated patients (P = 0.0007) and Cox multivariate regression confirmed centroid distance from baseline was associated with PFS when accounting for clinical factors (P = 0.0189). Lesion solidity was higher at recurrence compared to baseline (P = 0.0118). Tumors that progressed > 12 weeks after IMRT were significantly more spherical (P = 0.0094). CONCLUSION: Most GBMs recur local within therapeutic IMRT doses; however, tumors with longer PFS occurred further from the original tumor location and were more solid and/or nodular. Springer US 2022-09-02 2022 /pmc/articles/PMC9622513/ /pubmed/36053452 http://dx.doi.org/10.1007/s11060-022-04123-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Shidoh, Satoka Savjani, Ricky R. Cho, Nicholas S. Ullman, Henrik E. Hagiwara, Akifumi Raymond, Catalina Lai, Albert Nghiemphu, Phionah L. Liau, Linda M. Pope, Whitney B. Cloughesy, Timothy F. Kaprealian, Tania B. Salamon, Noriko Ellingson, Benjamin M. Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation |
title | Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation |
title_full | Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation |
title_fullStr | Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation |
title_full_unstemmed | Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation |
title_short | Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation |
title_sort | relapse patterns and radiation dose exposure in idh wild-type glioblastoma at first radiographic recurrence following chemoradiation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622513/ https://www.ncbi.nlm.nih.gov/pubmed/36053452 http://dx.doi.org/10.1007/s11060-022-04123-3 |
work_keys_str_mv | AT shidohsatoka relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT savjanirickyr relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT chonicholass relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT ullmanhenrike relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT hagiwaraakifumi relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT raymondcatalina relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT laialbert relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT nghiemphuphionahl relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT liaulindam relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT popewhitneyb relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT cloughesytimothyf relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT kaprealiantaniab relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT salamonnoriko relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation AT ellingsonbenjaminm relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation |